Corporate and Regional Press Releases

Please find below a list of our press releases.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

25 Jul 2017

Vancouver’s EVA Vein Care Now Offers New Varicose Vein Treatment

Minimally Invasive Non-Surgical Procedure Now Available in Time for Summer

16 Jun 2017

ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions in New Orleans, June 14 to 17.

10 Jun 2017

New study shows IO Loop™ improves patient follow-up, engagement and satisfaction following treatment with TheraSphere®

Study shows patients treated with TheraSphere® maintain quality of life throughout 90 day post-treatment period

22 May 2017

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

19 May 2017

BTG and HealthLoop collaborate on IO Loop™, an exclusive service to connect patients and interventional oncologists throughout treatment

Data from a pilot study using IO Loop™ with TheraSphere® (a 90Y transarterial radioembolisation therapy) will be presented at the World Conference on Interventional Oncology

20 Apr 2017

First European Patients Treated With DC Bead LUMI™ Radiopaque Drug-Eluting Beads

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of the first patients in the EU with DC Bead LUMI™.

7 Mar 2017

BTG announces CE Mark Certification for DC Bead LUMI™, the first commercially available radiopaque drug-eluting bead in the EU

DC Bead LUMI™ provides real-time visible, lasting confirmation of bead location during and post-embolisation of hypervascular tumours in the liver

27 Feb 2017

BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

BTG plc (LSE: BTG), the global specialist healthcare company, today announced U.S. Food and Drug Administration 510(k) clearance has been granted to the EKOS® Control Unit 4.0.

15 Feb 2017

BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology